Tylenol parent Kenvue Inc (NASDAQ:KVUE) is up 1.4% to trade at $21.64, after the company fired its CEO Thibaut Mongon amid efforts to revamp performance. Mongon also stepped down from his position on the board, as Kirk Perry was named interim CEO. This marks the second C-suite shakeup for Kenvue this year, after Chief Financial Officer (CFO) Paul Ruh was replaced with Amit Banati in May. The company also said tariffs could create a negative impact of up to $150 million.KVUE is eyeing a fourth-straight win, ...

ROCKVILLE, Md. and SUZHOU, China, July 14, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) (“Ascentage” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced the pricing of 22 million ordinary shares, par value $0.0001 per share, of the Company (the “Placement Shares”), at a price of HKD68.60 per share, in the offering by Dajun Yang Dynasty Trust, an affiliate of the Company’s Chief Executiv ...

Bain Capital has agreed to make an investment in PCI Pharma Services, a drug services provider that helps assemble and package medicines https://t.co/KK8mEiFPx6 ...

The upcoming report from Abbott (ABT) is expected to reveal quarterly earnings of $1.25 per share, indicating an increase of 9.7% compared to the year-ago period. Analysts forecast revenues of $11.07 billion, representing an increase of 6.7% year over year.The current level reflects a downward revision of 0.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Ahea ...

CHONGQING, CHINA - JULY 13: In this photo illustration, a smartphone displaying the logo of Johnson ... More & Johnson (NYSE: JNJ), a leading American multinational corporation known for pharmaceuticals, medical devices, and consumer health products, is held in front of a screen showing the company's latest stock market chart on July 13, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)Getty Images Johnson & Johnson (NYSE:JNJ) is set to report its earnings on Wednesday, July 16, 2025. ...

Group 1 - Momentum investors focus on "buying high and selling higher" rather than traditional strategies of buying low and waiting for recovery [1] - Fast-moving trending stocks can lose momentum if their future growth does not justify their high valuations, leading to potential downside risks for investors [2] - Investing in bargain stocks that have recently shown price momentum can be a safer strategy, with tools like the Zacks Momentum Style Score aiding in identifying such stocks [3] Group 2 - Fortress Biotech (FBIO) has shown a price increase of 2.2% over the past four weeks, indicating growing investor interest [4] - FBIO has gained 23.5% over the past 12 weeks, demonstrating its ability to deliver positive returns over a longer timeframe, with a beta of 1.75 indicating high volatility [5] - FBIO has a Momentum Score of B, suggesting it is an opportune time to invest in the stock [6] Group 3 - An upward trend in earnings estimate revisions has contributed to FBIO earning a Zacks Rank 2 (Buy), which is associated with strong momentum effects [7] - FBIO is trading at a Price-to-Sales ratio of 0.97, indicating it is reasonably valued at 97 cents for each dollar of sales [7] - FBIO appears to have significant growth potential while maintaining a fast pace, alongside other stocks that meet similar criteria [8] Group 4 - There are over 45 Zacks Premium Screens available for investors to find winning stock picks based on their personal investing styles [9] - The effectiveness of stock-picking strategies can be backtested using tools like the Zacks Research Wizard, which includes successful strategies [10]

Key Takeaways ABT's Q2 revenues are projected at $11.07B, up 6.7% year over year; EPS is estimated to rise 9.6% to $1.25. ABT's Medical Devices likely drove growth, led by CGMs, cardiac devices and TMVR system approval. Nutrition and EPD segments are expected to post modest to solid year-over-year revenue gains. Abbott Laboratories (ABT) is slated to report second-quarter 2025 results on July 17, before the opening bell.The company delivered adjusted earnings per share (EPS) of $1.09 in the last quarter, ...

Tevogen.AI’s model drastically reduces target analysis and has the potential to generate billions in cost savings across the healthcare system by streamlining early-stage drug discovery, reducing wet lab dependency, and accelerating timelines.Beyond cost savings, Tevogen.AI leadership believes AI-driven drug discovery has the potential to generate billions in top line revenues for companies who are early adopters.With virology datasets curated and alpha model created, Tevogen.AI will now apply PredicTcell t ...

LEO Pharma agreed to acquire the global rights for skin disease drug Spevigo from Boehringer, as the Danish dermatology specialist strengthens its portfolio ahead of a planned IPO in 2026 https://t.co/hCCBv5pCxI ...

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...